New Drug Approvals (Original) — May 19, 2026

SONROTOCLAX (BEGALZI) received FDA NME approval with Priority Review and Orphan Drug designations, signaling strong unmet need and a potential premium-priced therapy. This is the highest-value event in the period, with 7-year Orphan exclusivity and likely $100K-500K+/yr pricing.

ACCORD BIOPHARMA INC. received FDA approval for GOLIMUMAB-SLDI (IMMGOLIS), a biosimilar to Simponi (golimumab). This is bullish for ACCORD as it gains a share of the $2B+ TNF-inhibitor market, but bearish for Johnson & Johnson (originator) facing 30-60% revenue erosion over 2-3 years.

IONETIX received FDA approval for GALLIUM GA-68 GOZETOTIDE, a diagnostic imaging biosimilar approved via ANDA (unusual for a biosimilar), likely targeting PET imaging for neuroendocrine tumors or prostate cancer. This is bullish for IONETIX as a new revenue stream with lower development costs, but bearish for the undisclosed originator facing generic competition in a niche radiopharmaceutical market.

CHIESI FARMACEUTICI SPA received FDA label expansion approval for BECLOMETHASONE DIPROPIONATE, FORMOTEROL FUMARATE, AND GLYCOPYRROLATE (TRIMBOW), a triple-combination inhaler for COPD/asthma. This expands the addressable patient population and strengthens CHIESI’s respiratory franchise.

GOLIMUMAB-SLDI (IMMGOLIS) approval by ACCORD BIOPHARMA INC. introduces direct competition to Johnson & Johnson’s Simponi, a $2B+ TNF-inhibitor. Expect 30-60% revenue erosion over 2-3 years for the originator.

GALLIUM GA-68 GOZOTETIDE approval by IONETIX via ANDA introduces a lower-cost generic alternative in the radiopharmaceutical diagnostic market, eroding pricing power and market share for the undisclosed originator.

The approval of GALLIUM GA-68 GOZOTETIDE via ANDA rather than BLA is unusual for a biosimilar and may indicate it is a generic radiopharmaceutical. This creates regulatory uncertainty about interchangeability and automatic substitution status.

Several small-molecule biosimilars approved this period (FINERENONE, UBROGEPANT, CEFIXIME, TRETINOIN, TIVOZANIB, L-GLUTAMINE) may face IRA Medicare price negotiation at year 9 post-approval, limiting long-term revenue potential for sponsors.

SONROTOCLAX (BEGALZI) by BEONE MEDICINES USA is a high-value NME with Orphan Drug and Priority Review designations. Opportunity for premium pricing ($100K-500K+/yr) and rapid uptake in a niche indication.

GOLIMUMAB-SLDI (IMMGOLIS) by ACCORD BIOPHARMA INC. enters the $2B+ TNF-inhibitor market. Opportunity for significant market share capture given biosimilar discount (30-50% below Simponi).

GALLIUM GA-68 GOZOTETIDE by IONETIX enters the niche radiopharmaceutical diagnostic market. Opportunity for first-mover advantage with lower-cost generic pricing.

TRIMBOW label expansion by CHIESI FARMACEUTICI SPA expands the addressable patient population for this triple-combination inhaler, potentially driving incremental revenue in the respiratory market.

The period saw 10 biosimilar/generic approvals for small-molecule drugs (FINERENONE, UBROGEPANT, CEFIXIME, TRETINOIN, TIVOZANIB, L-GLUTAMINE, and two unknown from ALEMBIC and SANDOZ), indicating a wave of market access expansion in established therapeutic areas.

IONETIX’s GALLIUM GA-68 GOZOTETIDE approval via ANDA signals a potential shift toward generic competition in the radiopharmaceutical diagnostic space, which has traditionally been dominated by branded products.

The only NME approval (SONROTOCLAX by BEONE MEDICINES USA) with Orphan and Priority Review designations underscores the continued focus on rare disease therapies as high-value, premium-priced opportunities.

{"entity"=>"SONROTOCLAX (BEGALZI) - BEONE MEDICINES USA", "reason"=>"NME with Orphan Drug and Priority Review designations; highest-value approval in the period.", "trigger"=>"Commercial launch date; payer coverage decisions; first-quarter sales data"}

{"entity"=>"GOLIMUMAB-SLDI (IMMGOLIS) - ACCORD BIOPHARMA INC.", "reason"=>"Biosimilar entering $2B+ TNF-inhibitor market; significant revenue erosion risk for Johnson & Johnson.", "trigger"=>"Launch pricing strategy; first formulary wins at major PBMs; market share data"}

{"entity"=>"GALLIUM GA-68 GOZOTETIDE - IONETIX", "reason"=>"First-to-market diagnostic biosimilar via ANDA; regulatory uncertainty about interchangeability.", "trigger"=>"FDA clarification on interchangeability; launch date; formulary decisions at cancer centers"}

{"entity"=>"TRIMBOW - CHIESI FARMACEUTICI SPA", "reason"=>"Label expansion expands addressable population in respiratory market.", "trigger"=>"Updated prescribing guidelines; payer coverage for expanded indication"}